Source: Polaris Market Research Analysis Key Players & Competitive Analysis Report The GLP-1 sector is witnesses competition due to revenue growth opportunities in both developed and emerging markets
Use of Ozempic, a GLP-1 medication approved by the Food and Drug Administration (FDA) to treat diabetes, is increasing 75% (or $6.7 billion in spending) on a rolling 12-month average.1 This type of snowballing drug spend, if left unchecked, can cause plan premiums to soar, potentially pricing out members, leaving people who need drug coverage without the ability to pay for it
Another option, Oral Wegovya tablet form of semaglutideprovides a less invasive method for effective weight management
The flat-rate model ensures you can find your optimal therapeutic dose without worrying about escalating costs as your body adjusts and your provider increases your medication strength
Because these medications can play an important role in obesity treatment and blood sugar management, knowing how to use, store, and source them correctly can affect both results and cost
